Silence Therapeutics plc SLN

SLN Company Overview

Silence Therapeutics plc is a biotechnology company focused on the discovery and development of RNA interference (RNAi) therapeutics. The company develops short interfering RNA (siRNA) medicines designed to selectively silence disease-causing genes, with a primary focus on hematology, cardiovascular disease, and rare diseases. Silence Therapeutics operates within the biotechnology and pharmaceutical research industries and generates value primarily through proprietary therapeutic development programs, strategic licensing arrangements, and research collaborations with larger pharmaceutical companies.

The company’s core technology platform, known as mRNAi GOLD™, is designed to enable targeted delivery of siRNA molecules to specific tissues, particularly the liver, through GalNAc-based delivery approaches. Silence Therapeutics traces its origins to RNAi research activities established in Europe during the early 2000s and later evolved into a publicly traded biotechnology company listed on Nasdaq under the ticker SLN. Over time, the company shifted from broader RNA therapeutics exploration toward a more focused precision medicine strategy centered on gene silencing technologies and partnership-driven development.